imPORTND Patient-Oriented Research Training for Neuromuscular Disease Seeks Research Teams for Testing

The NMD4C is excited to introduce our online training platform “imPORTND”, created to help scientists engage with patient partners in research. These modules are designed for all neuromuscular research team members including researchers, staff, and patient partners.

imPORTND has been co-developed with a team of expert patient partners, clinicians, and researchers, and offer two modules to help scientists engage with patient partners in research. It is the first patient-oriented research training that focuses specifically on neuromuscular disease.

Acknowledging that all research participants come with different experiences and knowledge, the training platform is designed for users to decide what their own and their team learning needs are, and to select those activities which will be most helpful.

The NMD4C is seeking research teams to test the first two modules of the training platform before it fully launches later this fall. Please contact Patricia Mortenson or James Davis at or to sign up!

imPORTND - soft launch image

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.